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ASGE American Society for Gastrointestinal
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PIVI Preservation and Incorporation of
Valuable endoscopic Innovation
Tools like narrow band imaging (Olympus, Center
Valley, Pennsylvania, United States), confocal laser
microscopy (Mauna Kea Technologies, Paris,
France), and chromoendoscopy (sometimes with
magnification) have been used to successfully
predict the pathology of diminutive colon polyps
[1,2] as well as the presence of dysplasia in Bar-
rett’s esophagus [3–8]. Despite numerous publi-
cations demonstrating that these and other tools
can successfully predict pathology compared to
white light endoscopy, the influence of such im-
age enhancements in the routine clinical manage-
ment of colorectal polyps and Barrett’s esophagus
has been limited. Colorectal polyps, even when
diminutive (and with virtually no risk of malig-
nancy), are resected and consistently sent to pa-
thologists. This paradigm is costly and could be
replaced by the more cost-effective practice of es-
timating polyp pathology in real time during co-
lonoscopy, followed by resection of diminutive le-
sions without submission to the pathologist. This
new paradigm for management of diminutive
polyps, usually called resect and discard, was esti-
mated to allow over one billion dollars per year in
health care savings in the United States [9]. How-
ever, despite nearly 100 published trials showing
that trained and interested colonoscopists can
differentiate conventional adenomas from lesions
in the serrated class [1], resect and discard has yet
to enter clinical practice.
Similarly, endoscopists continue to manage Bar-
rett’s esophagus by examination of lesions in
white light, and if no nodules are identified, they
perform systematic biopsy at specified intervals,
but otherwise without direction. In clinical prac-
tice, these biopsies are frequently not obtained in
the recommended number [10]. Further, in ex-
pert hands, image enhanced inspection and di-
rected biopsy of Barrett’s esophagus has been
shown to improve the yield of dysplasia compared
to white light biopsies that may be systematic in
number and interval, but are not directed [3–8].
Clearly, it is sometimes difficult to implement
new paradigms in endoscopic and other medical
practices, even though evidence appears to sup-
port the paradigms and they pass the test of com-
mon sense.
In an attempt to salvage the clinical utility of
floundering endoscopic technologies, including
endoscopic imaging tools, The American Society
for Gastrointestinal Endoscopy (ASGE) initiated a
process it called Preservation and Incorporation
of Valuable endoscopic Innovation (PIVI) [11,12].
The idea of the PIVIs was that experts would first
delineate clinical problems where management
could potentially be improved by application of a
new endoscopic technology. Experts in the PIVI
topic would define the most clinically relevant
endpoints that should be addressed by investiga-
tors performing evaluations of the new technolo-
gy. The PIVIs also established performance
thresholds that should be achieved by the tech-
nology. The final step in the PIVI process is accom-
panied by an implied guarantee from the ASGE
that if the performance thresholds are met, ASGE
will endorse use of the new technology by appro-
priately trained and credentialed individuals as
an acceptable alternative for the management of
the originally defined clinical problem.
In this issue of Endoscopy International Open, Ap-
pannagari et al. remind us that incorporating new
endoscopic management paradigms can be com-
plex [13]. Approximately 20% of gastroenterolo-
gists responding to a survey indicated they would
be unwilling to incorporate the management
paradigm proposed in the ASGE Barrett’s esopha-
gus PIVI into their practice, because of concerns
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about medical-legal risk and lack of financial incentives. Given
that the survey was completed by either United States national
meeting attendees (who may be more willing than average to
try a new practice) or a tiny fraction (3.9%) of the email recipients
of the survey, we can reasonably conclude that 20% underesti-
mates the resistance to incorporating the Barrett’s esophagus
management protocol proposed by the PIVI and based on im-
age-enhanced endoscopy.
The●" Table1 lists the primary remaining obstacles to implemen-
tation of the new imaging-based management paradigms pro-
posed in the ASGE PIVIs for colorectal polyps and Barrett’s esoph-
agus [11,12]. The medical-legal concerns encountered in the
study by Appannagari will vary between countries that have dif-
ferent medical-legal environments, between states and regions
within the United States that have different laws and risk levels
pertaining to medical-legal malpractice, and between practition-
ers who have different levels of concern about medical-legal mat-
ters. The solution to these medical-legal concerns is the availabil-
ity of systems that provide long-term storage of high-definition
images or videos that memorialize the evidence used for an en-
doscopist’s real-time decisions regarding pathology [14]. This
image storage is exactly analogous to storage of radiographic
images and offers the consequent medical-legal risk and protec-
tion from risk afforded to radiologists by those images.
The issue of financial incentives is complex and sometimes linked
to medical-legal risk. Many physicians reasonably question why
they should undertake any practice that entails new medical-le-
gal risk and has no financial rewards. In Japan, endoscopists now
receive a payment (about $20 USD) for documenting use of im-
age-enhanced endoscopy. In the United States, there is now a
physician billing code for the use of confocal laser microscopy,
which in a strange twist is the real-time imaging technology
with the highest costs for implementation, is the least practical,
and takes the longest to learn. None of the other imaging tools
(narrow band imaging, Flexible spectral Imaging Color Enhance-
ment, iScan, autofluorescence, etc) have a billing code, and there
is currently no opportunity for reimbursement. The trend in the
United States has been progressive reductions in physician pay-
ments for endoscopy, and getting new payments from insurers
for use of these technologies seems unlikely. The best scenarios
for creation of financial incentives for image-based pathology
predictions appear to be payment schemes like “reference” and
“bundled” payments where endoscopists receive a fixed fee that
includes payment for the physician’s performance of the proce-
dure, the facility fee, the sedation costs, and the pathology fees
[15]. In a bundled payment system, endoscopists are incentivized
to use anesthesia specialists sparingly and tominimize pathology
costs. Without reference or bundled payments, the financial and
medical-legal disincentives to image-based pathology prediction
are real and substantial and should not be underestimated. One
need only look to the example of endoscopist directed propofol
to appreciate the power of these factors. Endoscopist directed
propofol was supported by extensive evidence [16], but created
medical-legal risk for endoscopists while simultaneously it pro-
duced no financial incentives and even created disincentives.
There is a way forward. In my opinion, there are two key steps.
The first key step is to acknowledge that when real-time image-
based management paradigms are endorsed by professional so-
cieties as effective and acceptable strategies for patient care, that
does not mean they are established as the standard of care and
must be used by every practitioner. Rather, endorsement of the
technologies means that they are an accepted alternative to the
current pathology-biopsy management paradigm. Clinicians will
have the option of incorporating these new practices, and may
choose to do so if the new paradigmmatches their interest, train-
ing, expertise, credentialing, and financial incentives. Endorse-
ment of the new paradigm by professional societies is also impor-
tant as the other half of medical-legal protection, because it sup-
ports those practitioners who decide to use the new standard of
care.
The second key step in moving forward is to transition the per-
formance-based thresholds proposed in the ASGE PIVIs from
technology-based thresholds to practitioner-based thresholds.
This step is an important correction that responds to the reports
of varying success in meeting the ASGE PIVI polyp thresholds and
better fits with how quality in the technical performance of diag-
nostic tests or therapeutic procedures is judged in clinical prac-
tice. To elaborate, the PIVI threshold targets have been achieved
for resect and discard in studies from academic centers [2,17,
18], but not in studies from private practice centers [19,20]. This
creates concern that the paradigm cannot be successfully imple-
mented in community practice and therefore should not be im-
plemented at all. The reality is that there would be many disin-
terested faculty members within the academic centers that pro-
duced successful studies who did not participate in the trials,
have not been trained in real-time polyp pathology interpreta-
tion, and should not be allowed to practice resect and discard.
Conversely, in community practice there were some colonosco-
pists who successfully met the PIVI thresholds even though
most of them did not [19]. Therefore, it makes sense to make re-
sect and discard a valid practice for any individual endoscopist,
regardless of the practice setting, who demonstrates that they
can meet the PIVI thresholds. Moving to an individual practition-
er-based competency model has the additional advantage of de-
emphasizing the competition between technologies. It is less im-
portant which technology a practitioner uses, as long as they can
meet the PIVI thresholds with the technology available. In reality,
this is how many endoscopic and surgical procedures are and
should be judged. For example, regardless of which endoscopes
are purchased by an endoscopy unit, each practitioner within
that unit should have an adequate adenoma detection rate [21].
Similarly, if a practitioner wants to implement resect and discard,
let them prove they are capable.
Everyone agrees that health care resources are spread increasing-
ly thin. There are several adjustments to current colonoscopy
practice that could reduce costs. For example, as adenoma detec-
tion rates increase with education and new technology, we could
Table 1 Remainingmeasures tomake real-time determination of pathology
a viable clinical practice for diminutive colorectal polyp management and
target biopsy in Barrett’s esophagus.1
Professional society endorsement
Development of credentialing protocols
Development of validated training tools
Documentation of endoscopic decision making (image storage)
– Medical-legal coverage
– Documentation of adenoma detection rate2
Revision of institutional policies on requirements to submit tissue
to pathology2
Reimbursement or other financial incentives for endoscopic
determination of pathology
1 Adapted from Rex, DK. Prediction of colorectal polyp pathologic lesions with image-
enhanced endoscopy: what will it take to make it matter? Gastrointest Endosc 2014;
80: 1088–1093 (reference number 14) with permission
2 Applies only to colorectal polyps
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allow colonoscopists with high adenoma detection rates to use
longer screening and surveillance intervals for low-risk colonos-
copy findings. Similarly, as adenoma and polyp detection rates
increase and newer colonoscopes permit detection of tiny lesions
that may never harm patients, we could ask: “Are we going to
continue to send every tiny polyp for an expensive pathologic as-
sessment?” Current practice often defies common sense. Going
forward, we need to demonstrate the will and courage to over-
come impediments to best and most cost-effective patient care.
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